Vestal Point Capital, LP
13F Reported Value
ⓘ$4.3B
Holdings
68
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Vestal Point Capital, LP disclosed 68 positions worth $4.3B in its Form 13F-HR for Q2 2026, led by $BMRN (BIOMARIN PHARMACEUTICAL INC) at 8.1% of the equity portfolio, followed by $NBIX and $ABVX. During the quarter the fund opened 9 new positions and exited 31 — including a new stake in $ABT and a full exit from $APGE. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Vestal Point Capital, LP’s Form 13F-HR filing with the SEC under CIK 1974915.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 58.2#1,029
Quality
$344.8M6,025,000 sh - 76.5#83
Quality
$316.8M1,880,000 sh - —
Quality
$313.1M2,349,443 sh - 71.3
Quality
$235.7M435,000 sh - —
Quality
$203.0M4,000,000 sh - 6.4
Quality
$195.3M8,050,000 sh - —
Quality
$155.9M5,250,000 sh - 4.9
Quality
$132.2M19,415,000 sh - 38.7
Quality
$128.4M1,575,000 sh - 65.5
Quality
$127.0M1,400,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2#1,029 | $344.8M | 6,025,000 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 76.5#83 | $316.8M | 1,880,000 |
 Abivax S.A.$ABVX | — | $313.1M | 2,349,443 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $235.7M | 435,000 |
 Enliven Therapeutics, Inc.$ELVN | — | $203.0M | 4,000,000 |
 Nurix Therapeutics, Inc.$NRIX | 6.4 | $195.3M | 8,050,000 |
 Bicara Therapeutics Inc.$BCAX | — | $155.9M | 5,250,000 |
 Taysha Gene Therapies, Inc.$TSHA | 4.9 | $132.2M | 19,415,000 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 38.7 | $128.4M | 1,575,000 |
 ABBOTT LABORATORIES$ABT | 65.5 | $127.0M | 1,400,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Vestal Point Capital, LP's 68 positions.
Showing top 10 of 68 holdings.
Sector Allocation
Healthcare
$4.3B
Full Holdings — Vestal Point Capital, LP (Q2 2026)
All 68 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $344.8M | 8.1% | +69% | 58.2 |
| 2 | $NBIX | NEUROCRINE BIOSCIENCES INC | $316.8M | 7.4% | +50% | 76.5 |
| 3 | $ABVX | Abivax S.A. | $313.1M | 7.3% | +57% | — |
| 4 | $UTHR | UNITED THERAPEUTICS Corp | $235.7M | 5.5% | +480% | 71.3 |
| 5 | $ELVN | Enliven Therapeutics, Inc. | $203.0M | 4.7% | +23% | — |
| 6 | $NRIX | Nurix Therapeutics, Inc. | $195.3M | 4.6% | +24% | 6.4 |
| 7 | $BCAX | Bicara Therapeutics Inc. | $155.9M | 3.6% | -3% | — |
| 8 | $TSHA | Taysha Gene Therapies, Inc. | $132.2M | 3.1% | +8% | 4.9 |
| 9 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $128.4M | 3.0% | -31% | 38.7 |
| 10 | $ABT | ABBOTT LABORATORIES | $127.0M | 3.0% | NEW | 65.5 |
| 11 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $120.5M | 2.8% | +637% | 65.7 |
| 12 |  $IRON | Disc Medicine, Inc. | $113.4M | 2.6% | +121% | — |
| 13 |  $GLUE | Monte Rosa Therapeutics, Inc. | $111.3M | 2.6% | +28% | 30.3 |
| 14 |  $PODD | INSULET CORP | $102.0M | 2.4% | +1224% | 71.3 |
| 15 |  $ASND | Ascendis Pharma A/S | $100.0M | 2.3% | +0% | 44.8 |
| 16 |  $AZN | ASTRAZENECA PLC | $85.3M | 2.0% | +350% | — |
| 17 |  $SNY | Sanofi | $85.3M | 2.0% | +43% | — |
| 18 |  $RVMD | Revolution Medicines, Inc. | $84.3M | 2.0% | -81% | — |
| 19 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $83.0M | 1.9% | +18% | 53.2 |
| 20 |  $DYN | Dyne Therapeutics, Inc. | $75.0M | 1.8% | -16% | — |
| 21 |  $NKTR | NEKTAR THERAPEUTICS | $69.8M | 1.6% | +251% | 9.7 |
| 22 |  $GMED | GLOBUS MEDICAL INC | $67.2M | 1.6% | +39% | 79.5 |
| 23 |  $TARS | Tarsus Pharmaceuticals, Inc. | $66.1M | 1.5% | +425% | 55 |
| 24 |  $IMTX | Immatics N.V. | $62.6M | 1.5% | +0% | — |
| 25 |  $TRVI | Trevi Therapeutics, Inc. | $57.8M | 1.4% | +43% | — |
| 26 |  $IMCR | Immunocore Holdings plc | $57.1M | 1.3% | -35% | — |
| 27 |  $RGEN | REPLIGEN CORP | $54.6M | 1.3% | -57% | 58.4 |
| 28 |  $BMY | BRISTOL MYERS SQUIBB CO | $46.1M | 1.1% | -20% | 70.4 |
| 29 |  $QURE | uniQure N.V. | $43.1M | 1.0% | +160% | — |
| 30 |  $XENE | Xenon Pharmaceuticals Inc. | $42.3M | 1.0% | +9% | 24 |
| 31 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $38.3M | 0.9% | +11% | — |
| 32 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $34.9M | 0.8% | +107% | 40.7 |
| 33 |  $ALC | ALCON INC | $33.5M | 0.8% | -38% | 54.9 |
| 34 |  $MYGN | MYRIAD GENETICS INC | $32.7M | 0.8% | +248% | 24.4 |
| 35 |  $RAPP | Rapport Therapeutics, Inc. | $30.4M | 0.7% | -49% | — |
| 36 |  $CBIO | CRESCENT BIOPHARMA, INC. | $29.3M | 0.7% | +9% | 9.6 |
| 37 |  $GEHC | GE HealthCare Technologies Inc. | $28.8M | 0.7% | +80% | 55.7 |
| 38 |  $INSM | INSMED Inc | $26.7M | 0.6% | NEW | 39.4 |
| 39 |  $VKTX | Viking Therapeutics, Inc. | $26.5M | 0.6% | -26% | — |
| 40 |  $BBNX | Beta Bionics, Inc. | $25.1M | 0.6% | -28% | 29.8 |
| 41 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $24.9M | 0.6% | +0% | 71 |
| 42 |  $SLDB | Solid Biosciences Inc. | $21.6M | 0.5% | -57% | — |
| 43 |  $ANRO | Alto Neuroscience, Inc. | $20.7M | 0.5% | -62% | — |
| 44 |  $TRAX | First Tracks Biotherapeutics, Inc. | $20.4M | 0.5% | NEW | — |
| 45 |  $LXEO | Lexeo Therapeutics, Inc. | $20.1M | 0.5% | -3% | — |
| 46 |  $SVRA | Savara Inc | $16.8M | 0.4% | +5% | — |
| 47 |  $DMRA | Damora Therapeutics, Inc. | $15.0M | 0.3% | -4% | — |
| 48 |  $SGP | SpyGlass Pharma, Inc. | $14.9M | 0.3% | +0% | — |
| 49 |  $TECX | Tectonic Therapeutic, Inc. | $14.6M | 0.3% | +30% | — |
| 50 |  $AVTX | Avalo Therapeutics, Inc. | $14.3M | 0.3% | NEW | 11.7 |
| 51 |  $EVMN | Evommune, Inc. | $13.3M | 0.3% | NEW | 14.9 |
| 52 |  $KLRA | Kailera Therapeutics, Inc. | $12.7M | 0.3% | NEW | — |
| 53 |  $AVR | Anteris Technologies Global Corp. | $9.9M | 0.2% | -12% | — |
| 54 |  $ZBIO | Zenas BioPharma, Inc. | $9.3M | 0.2% | +83% | 7.4 |
| 55 |  $VYGR | Voyager Therapeutics, Inc. | $9.2M | 0.2% | -13% | 8.1 |
| 56 |  $OKUR | OnKure Therapeutics, Inc. | $8.3M | 0.2% | -1% | — |
| 57 |  $SRZN | Surrozen, Inc./DE | $7.9M | 0.2% | -10% | — |
| 58 |  $MNPR | Monopar Therapeutics | $7.0M | 0.2% | +16% | — |
| 59 |  $ZURA | Zura Bio Ltd | $6.9M | 0.2% | +130% | — |
| 60 |  $OLMA | Olema Pharmaceuticals, Inc. | $5.2M | 0.1% | -2% | — |
| 61 |  $PALI | PALISADE BIO, INC. | $5.2M | 0.1% | +0% | — |
| 62 |  $IBIO | iBio, Inc. | $4.5M | 0.1% | NEW | 10.4 |
| 63 |  $SGMT | Sagimet Biosciences Inc. | $4.1M | 0.1% | NEW | — |
| 64 |  $ENGN | enGene Therapeutics Inc. | $2.9M | 0.1% | -23% | — |
| 65 |  $RZLT | Rezolute, Inc. | $2.0M | 0.1% | NEW | — |
| 66 |  $NYXH | Nyxoah SA | $1.4M | 0.0% | -3% | — |
| 67 |  $TENX | TENAX THERAPEUTICS, INC. | $777,537 | 0.0% | +0% | — |
| 68 |  $APRE | Aprea Therapeutics, Inc. | $280,805 | 0.0% | +0% | — |
New Positions (9)
Exited Positions (31)
$APGE Apogee Therapeutics, Inc.
$SRRK Scholar Rock Holding Corp
$VERA Vera Therapeutics, Inc.
$TERN Terns Pharmaceuticals, Inc.
$BSX BOSTON SCIENTIFIC CORP
$NUVL Nuvalent, Inc.
$COGT Cogent Biosciences, Inc.
$CLDX Celldex Therapeutics, Inc.
$KALV KalVista Pharmaceuticals, Inc.
$PTGX Protagonist Therapeutics, Inc
$DNLI Denali Therapeutics Inc.
$WAT WATERS CORP /DE/
$INSP Inspire Medical Systems, Inc.
$SLNO SOLENO THERAPEUTICS INC
$CYTK CYTOKINETICS INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Vestal Point Capital, LP including:
Track Vestal Point Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Vestal Point Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Vestal Point Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Vestal Point Capital, LP (SEC CIK: 1974915), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Vestal Point Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.